| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| Other Sizes |
| Toxicity/Toxicokinetics |
Interactions
Rats fed a diet containing 40% lactose for 5 days showed higher total cholesterol levels in their livers compared to the control group fed a basal sucrose diet. The lactose-added diet significantly reduced fecal sterol production, suggesting this result may be related to cholesterol absorption. Quantitative balance studies showed that the sucrose control group absorbed 40.4% of the administered cholesterol, while the lactose group absorbed 66.2% of the same dose. When lactose was added to the diet, both 2% and 4% calcium chloride inhibited cholesterol absorption; however, when sucrose was added, up to 4% calcium chloride was required to produce a similar effect… |
|---|---|
| References | |
| Additional Infomation |
Lactose is a white, hard crystalline powder. (NTP, 1992)
β-lactose is the β-isomer of lactose. It is a disaccharide composed of glucose and galactose, found in human and cow's milk. It is used in pharmaceuticals as tablets, in medicine as a nutrient, and in industry. It has been reported that St. John's wort contains β-lactose, and there is relevant data. It is a disaccharide composed of glucose and galactose, found in human and cow's milk. It is used in pharmaceuticals as tablets, in medicine as a nutrient, and in industry. |
| Exact Mass |
342.116
|
|---|---|
| CAS # |
63-42-3
|
| PubChem CID |
6134
|
| Appearance |
White, hard, crystalline mass of white powder
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
667.9±55.0 °C at 760 mmHg
|
| Melting Point |
222.8°C
|
| Flash Point |
357.8±31.5 °C
|
| Vapour Pressure |
0.0±4.6 mmHg at 25°C
|
| Index of Refraction |
1.652
|
| LogP |
-3.41
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
23
|
| Complexity |
382
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2O)O)O)CO)O)O)O)O
|
| InChi Key |
GUBGYTABKSRVRQ-DCSYEGIMSA-N
|
| InChi Code |
InChI=1S/C12H22O11/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17/h3-20H,1-2H2/t3-,4-,5+,6+,7-,8-,9-,10-,11-,12+/m1/s1
|
| Chemical Name |
(2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol
|
| Synonyms |
Lactose, anhydrous Lactose Galactinum Fast-flo
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~292.14 mM)
DMSO : ~50 mg/mL (~146.07 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.30 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.30 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.30 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 130 mg/mL (379.78 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05934318 | NOT YET RECRUITING | Dietary Supplement: L-citrulline | Fetal Growth Restriction Malaria Nutrition Placental Development |
Liverpool School of Tropical Medicine | 2023-09-30 | Not Applicable |
| NCT06152991 | ENROLLING BY INVITATION | Drug: GODEX Drug: Placebo |
Non-Alcoholic Fatty Liver Disease | Yoon Jun Kim | 2023-09-25 | Phase 3 |
| NCT01900184 | COMPLETED | Drug: QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)] Drug: Placebo |
Essential Hypertension | Quantum Genomics SA | 2012-12 | Phase 1 |
| NCT02087332 | UNKNOWN STATUS | Drug: Prolonged release Torasemide (Britomar) Drug: Torasemide (Diuver) |
Arterial Hypertension Chronic Heart Failure |
Society of Specialists in Heart Failure | 2014-04 | Phase 4 |
| NCT01246557 | COMPLETED | Drug: Lenalidomide Drug: Dexamethasone |
Chronic Lymphatic Leukemia | Hospital Universitari Vall d'Hebron Research Institute | 2009-12 | Phase 1 Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
